Menata-D Tablet contains a combination of Donepezil 5 mg and Memantine 10 mg, indicated for the management of moderate to severe Alzheimer's disease. Donepezil, a reversible acetylcholinesterase inhibitor, enhances cholinergic function by increasing the concentration of acetylcholine in the brain, thereby improving cognitive function and memory. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, modulates glutamatergic neurotransmission by blocking excessive NMDA receptor activity, which is implicated in neurodegeneration. The synergistic action of these agents aims to slow cognitive decline and improve behavioral symptoms associated with Alzheimer's disease. Menata-D is prescribed to patients exhibiting significant cognitive impairment and functional decline, where monotherapy has proven insufficient. The combination therapy is generally well-tolerated, with common adverse effects including dizziness, headache, gastrointestinal disturbances, and fatigue. Caution is advised in patients with renal impairment, cardiovascular conditions, or a history of seizures. Dosage should be individualized based on clinical response and tolerability, with regular monitoring recommended to assess efficacy and safety. Menata-D Tablet should be used under medical supervision as part of a comprehensive treatment plan including non-pharmacological interventions.